Shelby Dietrich, MD, helped establish one of the first hemophilia treatment centers in the US.
The AAVs being being investigated are designed to target the human liver, drawing on the organs potential to produce clotting factor.
The findings of a new study suggest several areas of impact relevant to adherence and physical activity for patients with severe hemophilia A.
Only one lot of Mononine® is included in this recall, all others are unaffected.
The opening of hemophilia B gene therapy trials to patients with little to no access to conventional treatments would be a pioneering advancement.
Researchers in Iran hope to achieve better outcomes for this vulnerable patient subgroup.
The investigators are working to build on factor VIIa’s established utility to stem bleeding, to one that can also prevent bleeding in both hemophilia A and B patients.
The case study featured in this CME-accredited online activity emphasizes the importance of collaborative care of the VWD patient over his or her lifetime and outlines the respective roles of primary care and hematology specialists.
The aim of the McGill researchers was to assess whether, under the proper clinical management, risk with this procedure was still greater in bleeding disorder patients.
The results showed that patients receiving on-demand therapy experienced a significantly greater number of bleeds than those patients in the prophylaxis group.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car